

Published in final edited form as:

ACS Med Chem Lett. 2012 October 11; 3(10): 799–803. doi:10.1021/ml300150y.

Syntheses of Siderophore-Drug Conjugates Using a Convergent Thiol-Maleimide System

Raúl E. Juárez-Hernández, Patricia A. Miller, and Marvin J. Miller*

Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA

Abstract

Three siderophore-drug conjugates (sideromycins) were synthesized by preparation of a maleimide linked derivative of the siderophore desferrioxamine B and reacting the corresponding Ga^{3+} -complex with freshly prepared thiol-containing antibiotics: loracarbef, ciprofloxacin and nadifloxacin. The conjugates and their synthetic precursors were tested against a broad panel of bacteria and were found to display Gram-positive selective, growth inhibitory activity (μM) indicating that this approach is suitable for the convergent synthesis and screening of novel sideromycins.

Keywords

antibiotic; drug-conjugate; siderophore

Siderophores are high affinity, Fe^{3+} -selective chelators produced by bacteria and fungi. Under iron deficient conditions, these molecules are secreted into the environment where they gather essential iron from diverse sources and deliver it to the producing organism.^{1–6} The biological importance of iron has prompted bacteria to develop means for the recognition of exogenous siderophores in order to gain a competitive advantage, which in turn has led to the biosyntheses of naturally occurring siderophore-drug conjugates (sideromycins) such as the albomycins,^{7–8} salmycins⁹ and microcins.^{10–11} These conjugates are modified siderophores containing an antibiotic portion that is delivered into a microorganism upon acquisition of the siderophore- Fe^{3+} complex.^{17–19} The inability to handle the actively transported drug might lead to cell death thus combating siderophore thievery.

Exploiting iron uptake as a biological target has been an exciting field for the study and development of new methods that allow the transport of antibacterial agents into pathogenic cells and a variety of synthetic sideromycins have been reported in the literature.^{12–19} One of the advantages of using these chelators as carriers is the often selective recognition of ferri-siderophores by microorganisms. Drug-conjugates of these molecules have been demonstrated to be highly potent antibiotic agents, stressing the value of their syntheses and study.

*Corresponding Author mmiller1@nd.edu.

ASSOCIATED CONTENT

Supporting Information

Experimental procedures of chemistry and microbiology, ^1H and ^{13}C NMR spectra of reported compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The authors declare no competing financial interest.

The assembly of these molecules however, is a chemically challenging effort that typically requires manipulation of protecting groups, and tailoring of conditions suitable to the drug or compound of interest. With the limited availability of some siderophores, it is highly desirable to minimize the number of steps needed to accomplish the conjugation and thus a convergent approach would provide a new tool towards these fascinating molecules. An example of versatile siderophore functionalization was the report by Koizumi and collaborators on conjugation of desferrioxamine B (DfoB) with monoclonal antibody OST7 (IgG1) to deliver radiogallium ^{67}Ga into tumors of mice,²⁰ for scintigraphic imaging, by employing three different strategies: 1) using glutaraldehyde as a linker, 2) acylation of both building blocks with 2-pyridyl disulfide and subsequent condensation via a disulfide bond and 3) linking a maleimide to DfoB and conjugation with the thiolcontaining antibody (Figure 1). In order to optimize the properties of the conjugates, and reduce radionuclide localization within non-targeted organs, a metabolizable maleimide linker (**2**) was later reported,²¹ indicating that specific characteristics of the conjugates could be modified by the linker of choice. Tinianow also reported the use of a maleimide-containing DfoB (**3**) to deliver ^{89}Zr using the monoclonal antibody thiotrastuzumab, for positron emission tomography (PET) imaging.²²

We are interested in the assembly of novel sideromycins through the previously described thiol-maleimide strategy, utilizing different siderophores. In this work, we explore the scope and limitations of this approach by conjugation of functionalized DfoB **12** (Figure 2) and thiol-containing antibiotics (e.g. **14**) to afford siderophore-drug conjugates such as Ga-DfoB-ciprofloxacin **17**.

The attachment of a thiol-containing linker to the drugs of interest: ampicillin, loracarbef, ciprofloxacin and nadifloxacin (representing drugs with different targets) was envisioned by the use of *S*-trityl protected acid **4**^{23–24} (Scheme 1), which was obtained from the condensation between 6-bromohexanoic acid and *S*-triphenylmethane thiol in the presence of DBU to afford the desired intermediate in 41% yield. Activated ester **5** was obtained from coupling fragment **4** with NHS using EDC•HCl. The resulting material could be purified by silica gel chromatography but was often found to be pure enough for further use after aqueous workup. Ampicillin was acylated by reaction with **5** in THF:H₂O:Et₃N to give the desired adduct in 30% yield. Optimized conditions allowed the isolation of drugderivatives loracarbef **7** (56% yield), ciprofloxacin **8** (51% yield) and nadifloxacin **9** (24% yield). The last was obtained from the EDC•HCl-mediated condensation between nadifloxacin and synthetic precursor **4**.

The maleimide-functionalized siderophore was obtained by reacting commercially available DfoB mesylate salt and freshly prepared NHS ester **10** under buffered conditions to give **11** in 50% yield (Scheme 2). Ga³⁺-complex **12** was isolated after refluxing the previous intermediate with Ga(acac)₃ in MeOH in 84% yield. We decided to use gallium as a protecting group for the hydroxamic chelators in DfoB. We were also interested in the potential role of gallium within our conjugates since growth inhibition of *Pseudomonas aeruginosa* has been reported in the literature with Ga(NO₃)₃,²⁵ GaCl₃ and Ga-DfoB.²⁶

Assembly of drug-conjugates. The removal of the *S*-trityl protecting group from intermediates **7–9** was achieved with a mixture of TFA (20% v/v) and *t*-Pr₃SiH (2% v/v) in deoxygenated CH₂Cl₂ (Scheme 2). Sulfur deprotection was monitored by TLC and the formation of the corresponding thiolcontaining drugs **13–15**, was confirmed by LCMS. We were unable to prove the formation of a thiol-ampicillin derivative from the deprotection of **6** or to detect any adduct from the conjugation with maleimide-Ga-DfoB **12**. Ga-DfoBloracarbef sideromycin **16** was obtained in 56% yield from the reaction between freshly prepared thiol **13**, maleimide **12** and DIPEA in deoxygenated THF. The

corresponding Ga-DfoB-ciprofloxacin **17** (24% yield) and Ga-DfoBnadifloxacin **18** (21% yield) were prepared in a similar fashion. The solvent used in the drug conjugation influenced product formation, when the assembly of **17** was attempted in CH₂Cl₂ the desired sideromycin was not detected even after 70 h.

Biological activity. The novel conjugates and their synthetic precursors were screened for antibacterial activity against a panel of Gram-positive and Gram-negative bacteria in an agar diffusion assay^{27–28} (Table S1, see SI). The *S*-trityl protected antibiotics displayed broad growth inhibition of bacteria (2 mM), with the exception of ciprofloxacin derivative **8**, where significant levels of precipitation were observed in aqueous media due to limited solubility. In general, *Mycobacterium smegmatis* and *Escherichia coli* were not affected by our compounds. To study the effect of gallium, we tested Ga(acac)₃ and Ga(NO₃)₃ but no growth inhibition (at 0.2 mM) was observed under the assay conditions. Maleimide-functionalized DfoB **11** and the corresponding Ga-DfoB complex **12** did not display antibiotic properties. However, drug-conjugates **16–18** were potent growth inhibitors, particularly against Gram-positive bacteria and *Mycobacterium vaccae*.

After susceptible bacteria were identified, MIC values were determined in MHII media as well as iron-deficient conditions (MHII+2,2'-bipyridine).²⁹ In MHII (Table 1), both *S*-trityl protected β -lactams **6** and **7**, displayed potent (MIC = 0.39–3.13 μ M) antibiotic activity against *B. subtilis*, *S. aureus* and *M. luteus*, comparable to loracarbef (MIC = 0.39–0.78 μ M). In the case of *M. vaccae*, derivative **7** (6.25 μ M) was more potent than the parent β -lactam (>25 μ M) possibly due to increased lipophilicity.

The MIC values of ciprofloxacin analog **8**, were not adequately determined because of its limited solubility in aqueous solution. However, nadifloxacin (Nadi) derivative **9** displayed improved solubility and a range of inhibitory activity (MIC = 3.13–>25 μ M) without enhancing the potency of Nadi. Consistent with our findings in the agar diffusion assay, Ga(NO₃)₃ and Ga-DfoB **12** did not display growth inhibition (MIC >50 μ M). *P. aeruginosa* (K799/wt) was not inhibited at the highest concentrations tested, in either MHII or iron-depleted media (MIC >50 μ M, Table S2, SI).

Ga-DfoB-loracarbef conjugate **16** retained the antibiotic activity of the β -lactam drug, while displaying remarkable inhibition of *M. luteus* (MIC = 0.001 μ M) enhancing the activity of Loracarbef (MIC = 0.39 μ M). While this result merits further study, the finding that *M. luteus* was strongly inhibited by **16** is consistent with the fact that it possesses a limited set of penicillin-binding proteins (PBPs) that render this Gram-positive bacteria particularly sensitive to β -lactam antibiotics.³⁰ Ga-DfoB-ciprofloxacin **17**, displayed reduced inhibition when compared to **16** (MIC = 31.25–>50 μ M), but enhanced solubility and therefore improved antibiotic activity over the *S*-trityl protected precursor **8**. Ga-DfoB-nadifloxacin conjugate **18** was a strong inhibitor of *B. subtilis* (MIC = >0.1 μ M) and *M. vaccae* (MIC = 3.13 μ M), consistent with the increased potency of Nadi when compared to Cipro.

Considering that Ga(NO₃)₃Ga(acac)₃ and Ga-DfoB **12** did not display growth inhibition under the different conditions tested, the observed antibiotic activity of sideromycins **16–18** can be attributed to a functional drug moiety. Our results are also consistent with bacterial internalization of the conjugates, as reflected by the growth inhibition of cytoplasmic targets with fluoroquinolone-based sideromycins (**17** and **18**). Recently, Rzhepishevskaya and collaborators reported the antibacterial properties of gallium citrate (Ga-Cit) and Ga-DfoB against Gram-positive and Gram-negative bacteria.³¹ Growth inhibition by gallium was affected by the metal-ligand and the media composition. IC₉₀ values for Ga-DfoB against several bacteria were higher (mM) than the concentrations screened in this work. To explore the effect of further iron-restricted conditions, we determined the MIC values in MHII

media with the addition of metal-chelator 2,2'-bipyridine (Table S2, see SI). In general, we observed comparable values between both assays, corroborating the displayed antibiotic activity of our synthetic compounds. Moderate enhancement (3-fold) was observed with loracarbef-conjugate **16** against *B. subtilis* and *S. aureus* (MIC = 3.9–7.8 μ M). The iron-depleted media was not conducive for the culturing of *M. vaccae*, which failed to grow after two attempts.

In conclusion, we have developed a convergent approach for the assembly of siderophore-drug conjugates using a thiol-maleimide strategy. As anticipated, the novel sideromycins displayed selective antibacterial properties and provided us with valuable information suitable for the study of these molecules. Because the siderophore of choice often determines the spectrum of activity of these conjugates, the described methodology could be expanded to the design of Gram-negative antibacterials through the use of an appropriate chelator.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge the University of Notre Dame and the NIH (AI 054193) for supporting this work. We appreciate constructive comments and advice regarding antibacterial studies from Dr. Ute Möllman, Jena, Germany. We gratefully acknowledge the use of the NMR facilities provided by the Lizzadro Magnetic Resonance Research Center at The University of Notre Dame (UND) and the mass spectrometry services provided by The UND Mass Spectrometry & Proteomics Facility (Mrs. N. Sevova, Dr. W. Boggess, and Dr. M. V. Joyce; supported by the National Science Foundation under CHE-0741793).

ABBREVIATIONS

DBU	1,8-diazabicycloundec-7-ene
DfoB	desferrioxamine B
Ga-DfoB	Ga ³⁺ -complex of DfoB
EDC•HCl	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl
LCMS	liquid chromatography mass spectrometry
MHII	Mueller-Hinton agar
MIC	minimum inhibitory concentration
NHS	<i>N</i> -hydroxysuccinimide
THF	tetrahydrofuran
TFA	trifluoroacetic acid
TLC	thin layer chromatography

REFERENCES

1. Miethke M, Marahiel MA. Siderophore-Based Iron Acquisition and Pathogen Control. Microbiol. Mol. Biol. Rev. 2007; 71:413–451. [PubMed: 17804665]
2. Boukhalfa H, Crumbliss AL. Chemical aspects of siderophore mediated iron transport. Biometals. 2002; 15:325–339. [PubMed: 12405526]
3. Andrews SC, Robinson AK, Rodríguez-Quinones F. Bacterial iron homeostasis. FEMS Microbiol. Rev. 2003; 27:215–237. [PubMed: 12829269]

4. Sandy M, Butler A. A Microbial Iron Acquisition: Marine and Terrestrial Siderophores. *Chem. Rev.* 2009; 109:4580–4595. [PubMed: 19772347]
5. Hider RC, Kong XL. Chemistry and biology of siderophores. *Nat. Prod. Rep.* 2010; 27:637–657. [PubMed: 20376388]
6. Braun V, Hantke K. Recent insights into iron import by bacteria. *Curr. Opin. Chem. Biol.* 2011; 15:328–334. [PubMed: 21277822]
7. Benz G, Schröder T, Kurz J, Wünsche C, Karl W, Steffen GJ, Pfitzner J, Schmidt D. Konstitution der Deferriform der Albomycine 61, 82 und e. *Ang. Chem. Int. Ed.* 1982; 94:552–553.
8. Braun V, Günthner K, Hantke K, Zimmerman L. Intracellular Activation of Albomycin in *Escherichia coli* and *Salmonella typhimurium*. *J. Bacteriol.* 1983; 156:308–315. [PubMed: 6352681]
9. Vértessy L, Aretz W, Fehlhaber H-W, Kogler H, Salmycin A-D. Antibiotics from *Streptomyces violaceus*, DSM 8286, Having a Siderophor-Aminoglycoside Structure. *Helv. Chim. Acta.* 1995; 78:46–60.
10. Duquesne S, Destoumieux-Garzón D, Peduzzi J, Rebuffat S. Microcins, gene-encoded antibacterial peptides from enterobacteria. *Nat. Prod. Rep.* 2007; 24:708–734. [PubMed: 17653356]
11. Nolan EM, Fischbach MA, Koglin A, Walsh CT. Biosynthetic Tailoring of Microcin E492m: Post-translational Modification Affords an Antibacterial Siderophore-Peptide Conjugate. *J. Am. Chem. Soc.* 2007; 129:14336–14347. [PubMed: 17973380]
12. Dong L, Roosenberg II JM, Miller MJ. Total Synthesis of Desferrisalmycin B. *J. Am. Chem. Soc.* 2002; 124:15001–15005. [PubMed: 12475343]
13. Bernier G, Girijavallabhan V, Murray A, Niyaz N, Ding P, Miller MJ, Malouin F. Desketoneoenactin-Siderophore Conjugates for *Candida*: Evidence of Iron Transport-Dependent Species Selectivity. *Antimicrob. Agents Chemother.* 2005; 49:241–248. [PubMed: 15616301]
14. Yoganathan S, Sit CS, Vederas JC. Chemical synthesis and biological evaluation of gallidermin-siderophore conjugates. *Org. Biomol. Chem.* 2011; 9:2133–2141. [PubMed: 21290068]
15. Miller MJ, Walz AJ, Zhu H, Wu C, Moraski G, Möllmann U, Tristani EM, Crumbliss AL, Ferdig MT, Checkley L, Edwards RL, Boshoff HI. Design, Synthesis, and Study of a Mycobactin-Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and Malaria. *J. Am. Chem. Soc.* 2011; 133:2076–2079. [PubMed: 21275374]
16. Roosenberg II JM, Lin YM, Lu Y, Miller MJ. Studies and Syntheses of Siderophores, Microbial Iron Chelators, and Analogs as Potential Drug Delivery Agents. *Curr. Med. Chem.* 2000; 7:159–197. [PubMed: 10637361]
17. Braun V, Pramanik A, Gwinner T, Koeberle M, Bohn E. Sideromycins: tools and antibiotics. *Biometals.* 2009; 22:3–13. [PubMed: 19130258]
18. Chu BC, Garcia-Herrero A, Johanson TH, Krewulak KD, Lau CK, Peacock RS, Slavinskaya Z, Vogel HJ. Siderophore uptake in bacteria and the battle for iron with the host; a bird's eye view. *Biometals.* 2010; 23:601–611. [PubMed: 20596754]
19. Ji C, Juárez-Hernández RE, Miller MJ. Exploiting bacterial iron acquisition: siderophore conjugates. *Future Med. Chem.* 2012; 4:297–313. [PubMed: 22393938]
20. Koizumi M, Endo K, Kunimatsu M, Sakahara H, Nakashima T, Kawamura Y, Watanabe Y, Saga T, Konishi J, Yamamuro T, Hosoi S, Toyama S, Arano Y, Yokohama A. ⁶⁷Ga-labeled Antibodies for Immunoscintigraphy and Evaluation of Tumor Targeting and Drug-Antibody Conjugates in Mice. *Cancer Res.* 1988; 48:1189–1194. [PubMed: 3422590]
21. Arano Y, Matsushima H, Tagawa M, Koizumi M, Endo K, Konishi J, Yokoyama A. A Novel Bifunctional Metabolizable Linker for the Conjugation of Antibodies with Radionuclides. *Bioconjugate Chem.* 1991; 2:71–76.
22. Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, Vandlen R, Darwish M, Junutula JR, Williams S-P, Marik J. Site-specifically ⁸⁹Zr-labeled monoclonal antibodies for ImmunoPET. *Nucl. Med. Biol.* 2010; 37:289–297. [PubMed: 20346868]
23. Collman JP, Groh SE. "Mercaptan-Tail" Porphyrins: Synthetic Analogues for the Active Site of Cytochrome P-450. *J. Am Chem. Soc.* 1982; 104:1391–1403.

24. Moreno AY, Mayorov AV, Janda KD. Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine. *J. Am. Chem. Soc.* 2011; 133:6587–6595. [PubMed: 21473576]
25. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK. The transition metal gallium disrupts *Pseudomonas aeruginosa* iron metabolism and has antimicrobial and antibiofilm activity. *J. Clin. Invest.* 2007; 117:877–888. [PubMed: 17364024]
26. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E. The potential of desferrioxamine-gallium as an anti-*Pseudomonas* therapeutic agent. *Proc. Natl. Acad. Sci. USA.* 2008; 105:16761–16766. [PubMed: 18931304]
27. General description of the modified Kirby-Bauer agar diffusion assay used in this work: Afonin S, Glaser RW, Berditchevskaia M, Wadhvani P, Gührs K-H, Möllmann U, Perner A, Ulrich AS. 4-Fluoro-phenylglycine as a Label for 19F-NMR Structure Analysis of Membrane Associated Peptides. *ChemBioChem.* 2003; 4:1151–1163. [PubMed: 14613106]
28. Murray, PR.; Baron, EJ.; Pfaller, MA.; Tenover, FC.; Tenover, RH. *Manual of Clinical Microbiology*. 7th ed.. Washington, DC: American Society for Microbiology; 1999.
29. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*. 8th ed.. Villanova, PA: Clinical and Laboratory Standards Institute (CLSI); 2009. approved standard document M07-A7.
30. Young M, Artsatbanov V, Beller HR, Chandra G, Chater KF, Dover LG, Goh E-B, Kahan T, Kaprelyants AS, Kyripides N, Lapidus A, Lowry SR, Lykidis A, Mahillon J, Markowitz V, Mavromatis K, Mukamolova GV, Oren A, Rokem JS, Smith MCM, Young DI, Greenblatt CL. Genome Sequence of the Fleming Strain of *Micrococcus luteus*, a Simple Free-Living Actinobacterium. *J. Bacteriol.* 2010; 192:841–860. [PubMed: 19948807]
31. Rzhapishvskaya O, Ekstrand-Hammarström B, Popp M, Björn E, Buch A, Sjöstedt A, Antti H, Ramstedt M. Antimicrob. Agents Chemother. 2011; 55:5568–5580. [PubMed: 21947396]




Figure 1.
Use of maleimide linkers for the functionalization of DfoB.^{20–22}




Figure 2.
Use of maleimide-DfoB **12** and thiol-ciprofloxacin **14** in the synthesis of sideromycin **17**.






Figure 3.
Ga-DfoB-nadifloxacin conjugate **18**.



Scheme 1.
Syntheses of thiol-containing antibiotic precursors



ACS Med Chem Lett. Author manuscript; available in PMC 2013 October 11.

Table 1
Minimum Inhibitory Concentration of compounds (MIC μ M) determined in MHII media^{a, b, c, d}

Compound	<i>B. subtilis</i> ATCC 6633	<i>S. aureus</i> SG511	<i>M. luteus</i> ATCC 10240	<i>M. vaccae</i> IMET 10670	<i>P. aeruginosa</i> K799/wt
6^c	2.15 ^b	0.39 ^b	1.19	>25	>25 ^b
7^c	3.13 ^b	2.35 ^b	1.71	6.25	>25 ^b
8^c	>25 ^b P	>25 ^b	>25 ^b	>25 P	>25 ^b
9^c	3.13	25	>25	10.4	>25
Ga(NO₃)₃^c	>25	>25	>25	>25	>25
12^c	>50 ^b	>50 ^b	>50 ^b	>50	>50 ^b
16^c	27	9.38 ^b	0.001	>50	>50 ^b
17^c	>50 ^b	31.25 ^b	>50 ^b	>50	>50 ^b
18^c	<0.1	12.5	50	3.13	>50
Lora^c	0.46	0.78	0.39	>25	>25
Nadi^c	0.008	0.06	0.20	0.06	>2
Cipro	0.06	0.47	7.54	0.24	0.94

^aMICs were determined by the visual end point broth microdilution method following CLSI guidelines.²⁹

^bReported values are the average of two sets of duplicates ($N=4$).

^cReported values are the average of triplicates ($N=3$).

^dP, observed precipitation.